Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

23andMe Holding Co. - Common Stock (NQ: ME )

3.170 -0.040 (-1.25%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 23andMe Holding Co. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
23andMe to Report FY2024 First Quarter Financial Results
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
From 23andMe, Inc.
Via GlobeNewswire
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of... 
From 23andMe, Inc.
Via GlobeNewswire
23andMe Holding's Return On Capital Employed Overview
Via Benzinga
Recap: 23andMe Holding Q4 Earnings
Via Benzinga
23andMe Holding's Earnings Outlook
Via Benzinga
This Genetics Stock Could Have Massive Long-Term Potential
This healthcare company isn't without risk but is doing a good job executing on its vision. 
Via The Motley Fool
3 Gene Testing Stocks to Buy Before They Take Off
The future of gene testing is bright thanks to an aging population. Here are three companies leading the industry. 
Via InvestorPlace
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe, Inc.
Via GlobeNewswire
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Neither has a traditional business model, but that could be an asset for both. 
Via The Motley Fool
3 Key Biotech Trends for 2023 And Beyond
New opportunities are becoming apparent, but so are fresh risks in the biotech field. 
Via The Motley Fool
Hero or Zero? 3 High-Risk Penny Stocks to Make You Rich … or Broke.
Explore the world of high-risk penny stocks, with their potential for significant returns, as we analyze three speculative opportunities. 
Via InvestorPlace
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
From 23andMe, Inc.
Via GlobeNewswire
3 Personalized Medicine Stocks to Buy for Long-Time Returns
Personalized medicine is the future of medicine. Here are three personalized medicine stocks to invest in so you don't miss out. 
Via InvestorPlace
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Releases New Report Revealing Likelihood of Developing Lupus
23andMe+ members can now gain insights on the chronic autoimmune condition 
From 23andMe Holding Co.
Via GlobeNewswire
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
Afkhami joins 23andMe with more than 20 years of experience in corporate development and strategy 
From 23andMe Holding Co.
Via GlobeNewswire
BELLUS Health, Sunrun And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
From 23andMe Holding Co.
Via GlobeNewswire
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
From 23andMe Holding Co.
Via GlobeNewswire
23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease
Company teams up with Novartis on Lipoprotein(a) education for 23andMe customers 
From 23andMe Holding Co.
Via GlobeNewswire
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Biotechs with an AI strategy are likely to be the first to flourish from the disruptions. 
Via The Motley Fool
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented 
From 23andMe Holding Co.
Via GlobeNewswire
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
They've been using machine learning for years, and now they might do even more. 
Via The Motley Fool
New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare
From 23andMe Holding Co.
Via GlobeNewswire
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
There's nothing better than getting a bargain that'll pay off for years. 
Via The Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Both are likely to double quite soon, and they aren't even that risky. 
Via The Motley Fool
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and... 
From 23andMe Holding Co.
Via GlobeNewswire
23andMe to Present at Upcoming Investor Conferences
From 23andMe Holding Co.
Via GlobeNewswire
Why Tivic Health Systems Are Trading Lower By 55%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Hempacco Co., Inc. (NASDAQ: HPCO) rose 296% to $2.99 after declining 6% on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.